Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lewy Body Parkinson Disease Clear all
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2
Biological · Radiation · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
68
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 1:26 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Olaparib, Placebo for olaparib, Etoposide, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Thoracic Radiotherapy, Durvalumab
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
33
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 1:26 AM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Lewy Body Dementia, Parkinson Disease Dementia, Dementia With Lewy Bodies, Lewy Body Disease
Interventions
Peer Mentor Support and Caregiver Education, Caregiver Education
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced May 22, 2026, 1:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Gebasaxturev, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Hackensack, New Jersey • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Parkinson Disease (PD), Lewy Body Dementia (LBD)
Interventions
18F-MFBG
Drug
Lead sponsor
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Biliary Tract Carcinoma
Interventions
Pembrolizumab, Gemcitabine, Cisplatin, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
UC (Urothelial Cancer)
Interventions
Pembrolizumab, Epacadostat, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Tucson, Arizona • Orange, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo, TACE
Drug · Biological · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
59
States / cities
Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 22, 2026, 1:26 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Lewy Body Dementia, Parkinson Disease Dementia, Dementia With Lewy Bodies
Interventions
Survey
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced May 22, 2026, 1:26 AM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors
Interventions
Selumetinib, Pembrolizumab
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Duarte, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
Pembrolizumab, Placebo, Cisplatin, Capecitabine, 5-fluorouracil, Docetaxel, Oxaliplatin, Leucovorin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
14
States / cities
Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pembrolizumab, Enzalutamide
Drug
Lead sponsor
Mark Garzotto, MD
Federal
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced May 22, 2026, 1:26 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Placebo
Radiation · Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced May 22, 2026, 1:26 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Redwood City, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Billings, Montana • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced May 22, 2026, 1:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Vibostolimab/Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 22, 2026, 1:26 AM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
200 mg of pembrolizumab, V938
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
San Francisco, California • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced May 22, 2026, 1:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor, Multiple System Atrophy, Drug Induced Parkinson's Disease, Diffuse Lewy Body Disease, Myasthenia Gravis, Spinal Cord Injuries
Interventions
Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation, Peripheral Nerve Stimulation
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced May 22, 2026, 1:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
AZD2936
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 22, 2026, 1:26 AM EDT
Active, not recruiting Phase 4 Interventional
View directory record Official record
Conditions
Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
Interventions
Zoledronic Acid 5Mg/Bag 100Ml Inj, Placebo
Drug · Other
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
60 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
77
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Lewy Body Dementia, Parkinson Disease
Interventions
Sitagliptin, Dapagliflozin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
27
States / cities
Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2022 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Interventions
Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Patritumab Deruxtecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 1:26 AM EDT